2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Efficacy and safety of zonisamide in patients with dementia with Lewy bodies with parkinsonism: pooled analysis of phase 2 and 3 trials

J. Goldman, K. Hasegawa, T. Odawara, K. Kochi, H. Maruyama, O. Konishi, S. Toya, K. Kosaka, M. Murata, I. Mckeith (Chicago, IL, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Efficacy of carbidopa/levodopa enteral suspension (CLES) in advanced Parkinson’s disease patients previously treated with deep brain stimulation (DBS) – A subgroup analysis from PROviDE study

S. Isaacson, R. Pahwa, S. Thakkar, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred (Boca Raton, FL, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Efficacy of Istradefylline, an A2A Receptor Antagonist, When Added to Levodopa (LD) and Other Medications for Parkinson’s Disease (PD)

P. Lewitt, N. Hattori, A. Mori, K. Toyama, E. Ohta, P. Salzman, S. Isaacson (West Bloomfield, MI, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Efficacy of Motor Imagery Questionnaire-RS as a Diagnostic Tool in Rehabilitation of Movement Disorders

D. Kaur, N. Bhardwaj, S. Kumari, S. Kumari, A. Gupta, G. Kumar (Patna, India)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.

A. Lees, J. Ferreira, O. Rascol, W. Poewe, F. Stocchi, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: a post-hoc analysis from combined BIPARK-I and II

A. Lees, J. Ferreira, A. Antonini, H. Reichmann, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: a post-hoc analysis from combined BIPARK-I and II

A. Lees, J. Ferreira, O. Rascol, W. Poewe, E. Tolosa, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and Clinical Global Impression of Change from the BIPARK-I double-blind experience

J. Rocha, F. Stocchi, A. Lees, J. Ferreira, W. Poewe, O. Rascol, A. Santos, D. Magalhães, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Efficacy, Safety and Tolerability of Tavapadon in Subjects With Early Stage Parkinson’s Disease

D. Gray, R. Riesenberg, J. Werth, Y. Zhang, M. Versavel, S. Duvvuri (Boston, MA, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Electroconvulsive Therapy (ECT): An Effective Option for the Treatment of Medication-Resistant Psychiatric Symptoms in Huntington’s Disease: A Case Series and Review of the Literature

J. Adrissi, N. Nadkarni, E. Gausche, D. Bega (Chicago, IL, USA)

Huntington’s Disease  ·  Agora 3 West, Level 3